The results presented above demonstrate the ability of KRASG12C inhibitors to reverse KRAS-driven immune evasion mechanisms, such as enhancing tumor cell–intrinsic IFN responses and modulating the expression of secreted immunomodulatory factors. The gene discussed is KRAS; the disease is neoplasm.